On Nov 08, major Wall Street analysts update their ratings for $Tandem Diabetes Care (TNDM.US)$, with price targets ranging from $40 to $75.
Barclays analyst Matt Miksic maintains with a buy rating, and adjusts the target price from $58 to $60.
UBS analyst Danielle Antalffy maintains with a hold rating, and maintains the target price at $40.
TD Cowen analyst Josh Jennings maintains with a buy rating, and maintains the target price at $45.
Stifel analyst Mathew Blackman maintains with a buy rating, and maintains the target price at $60.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and maintains the target price at $65.
Furthermore, according to the comprehensive report, the opinions of $Tandem Diabetes Care (TNDM.US)$'s main analysts recently are as follows:
Tandem Diabetes delivered another solid growth quarter, with an increase in full-year growth guidance to 17%-18%. This performance is largely driven by the continued success of the Mobi launch.
Although Tandem Diabetes has reported its third consecutive quarter of surpassing expectations and raising forecasts, the company's stock performance did not reflect these positive results, which may be due to uncertainties about future growth prospects. It is suggested that the company has completely navigated through its previous challenges and that the fundamental aspects of the business are expected to progressively enhance going forward. Nevertheless, a more cautious stance is being maintained until there is greater assurance in the enduring factors that will drive sales growth.
Concerns regarding Tandem Diabetes' third-quarter revenue outperformance were noted, with contributing factors including timing benefits from U.S. supplies and orders from international distributors. United States pump shipments for the quarter were reported to align closely with expectations.
Here are the latest investment ratings and price targets for $Tandem Diabetes Care (TNDM.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月8日，多家华尔街大行更新了$Tandem Diabetes Care (TNDM.US)$的评级，目标价介于40美元至75美元。
巴克莱银行分析师Matt Miksic维持买入评级，并将目标价从58美元上调至60美元。
瑞士银行分析师Danielle Antalffy维持持有评级，维持目标价40美元。
TD Cowen分析师Josh Jennings维持买入评级，维持目标价45美元。
斯迪富分析师Mathew Blackman维持买入评级，维持目标价60美元。
加皇资本市场分析师Shagun Singh Chadha维持买入评级，维持目标价65美元。
此外，综合报道，$Tandem Diabetes Care (TNDM.US)$近期主要分析师观点如下：
Tandem Diabetes交付了另一个强劲增长季度，全年增长预期提高至17%-18%。这一业绩主要受到Mobi推出持续成功的推动。
尽管Tandem Diabetes已经报告了第三个连续超过预期并提高预测的季度，但该公司的股票表现并未反映这些积极结果，可能是由于对未来增长前景的不确定性。建议该公司已完全应对了之前的挑战，并且业务的基本方面预计将逐步提升。然而，在对未来推动销售增长的持久因素更有把握之前，仍需保持更为谨慎的态度。
有关Tandem Diabetes第三季度营业收入表现强劲的担忧，指出了一些影响因素，包括来自美国供应商的时机利益以及国际分销商的订单。第三季度美国泵的装运量报告显示与预期紧密对齐。
以下为今日8位分析师对$Tandem Diabetes Care (TNDM.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
